RBC Capital analyst Randall Stanicky called Amneal Pharmaceuticals (NYSE: AMRX) their top generic idea heading into 2019 and best aligned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE